What CinDome Pharma does

CinDome Pharma, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2019 and headquartered at 5375 Medpace Way in Cincinnati, Ohio. The company operates as a lean portfolio company within the CinRx Pharma hub-and-spoke model, relying on the central CinRx team of scientific, technical, and clinical development experts rather than maintaining a large standalone organization (employee count disclosed as 11–50). CinDome is advancing a single drug candidate, deudomperidone (CIN-102), through Phase 2 clinical trials as a potential first FDA-approved long-term treatment for chronic gastroparesis in the United States.

The core technology is a new chemical entity built on deuteration and novel formulation of domperidone, a dopamine D2/D3 antagonist widely used as first-line therapy outside the U.S. but not approved domestically due to QT prolongation cardiovascular risk. Deudomperidone has been engineered to alter the pharmacokinetic profile for sustained prokinetic and antiemetic efficacy while significantly reducing cardiac liability. The clinical program consists of two parallel randomized, double-blind, placebo-controlled Phase 2 trials: envision3D in diabetic gastroparesis (~400 subjects, enrollment complete September 2025) and envisionGI in idiopathic gastroparesis (~400 subjects, enrollment complete March 2026, topline data expected late 2026). Earlier Phase 1 and Phase 2a studies established a favorable safety profile with no meaningful QT impact at supratherapeutic exposures and demonstrated target engagement with improved gastric emptying time.

The business model is a traditional clinical-stage biopharmaceutical model with no current revenue and no disclosed pricing. Commercialization, if FDA approval is obtained, is expected to follow a sales-led motion targeting gastroenterologists and gastrointestinal specialists in the U.S. market through specialty pharmacy and prescription pharmaceutical distribution channels. To date, CinDome has raised $59 million in total funding (a $19 million initial Series B in April 2023 and a $40 million Series B extension in May 2024) from existing investors CinRx Pharma and Perceptive Advisors. The company addresses an estimated 12–16 million U.S. patients with gastroparesis, with the U.S. market forecasted to exceed $4 billion by 2030.

Name

CinDome Pharma

Legal name

CinDome Pharma, Inc.

Website

https://cindome.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

CinDome Pharma is a clinical-stage biopharmaceutical company developing deudomperidone (CIN-102), a deuterated formulation of domperidone engineered to reduce cardiac liability, as the first potential FDA-approved long-term treatment for chronic gastroparesis in the United States.

Ownership category

akta.pro rank

Product category

Gastroparesis Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Gastroparesis treatment
• Deuterated pharmaceuticals
• Dopamine antagonists
• Gastrointestinal drugs
• Novel chemical entity

Headquarters

HQ city

Cincinnati

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: CinDome Pharma is a clinical-stage biopharmaceutical company with no current revenue. Upon successful FDA approval, the company plans to commercialize deudomperidone (CIN-102) as a prescription drug for chronic gastroparesis, generating revenue through pharmaceutical product sales. Revenue model is anticipated to be a traditional prescription pharmaceutical product sold through specialty pharmacy and distribution channels.

Go-to-market motion1 record

Marketing channels4 records

Core offering

CinDome Pharma is developing deudomperidone (CIN-102), a novel deuterated formulation of the dopamine D2/D3 antagonist domperidone, as a chronic therapy for gastroparesis. The drug candidate is currently advancing through two parallel Phase 2 clinical trials (envision3D for diabetic gastroparesis and envisionGI for idiopathic gastroparesis) targeting an FDA-approved long-term treatment for an indication affecting 12-16 million Americans.

Product overview

CinDome Pharma is advancing a single drug candidate, deudomperidone (CIN-102), through Phase 2 clinical trials for the treatment of chronic gastroparesis. The company operates two parallel Phase 2 studies: envision3D for diabetic gastroparesis and envisionGI for idiopathic gastroparesis. The product is a novel formulation of domperidone designed to provide a safe, long-term treatment option where currently no FDA-approved chronic therapy exists.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Phase 2a trial demonstrated target engagement and improvement in gastric emptying time
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered minor.

• Massachusetts General Hospital (Brad Kuo, M.D.)minorOthersDr. Brad Kuo of Massachusetts General Hospital serves on CinDome Pharma's Scientific Advisory Board, providing clinical and scientific guidance to the company's gastroparesis drug development program.
• Texas Tech University Health Sciences Center (Richard McCallum, M.D.)minorOthersDr. Richard McCallum of Texas Tech University Health Sciences Center serves on CinDome Pharma's Scientific Advisory Board, providing clinical and scientific guidance to the company's gastroparesis drug development program.
• Temple University Hospital (Henry Parkman, M.D.)minorOthersDr. Henry Parkman of Temple University Hospital serves on CinDome Pharma's Scientific Advisory Board, providing clinical and scientific guidance to the company's gastroparesis drug development program.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Evoke Pharma: Evoke Pharma developed and commercializes Gimoti (metoclopramide nasal spray) for diabetic gastroparesis, making it the closest direct competitor to CinDome in the U.S. gastroparesis space. It is highly comparable as a small-cap, gastroparesis-focused company targeting the same patient population and prescriber base (gastroenterologists).

Emerging players

• Processa Pharmaceuticals: Processa Pharmaceuticals is developing PCS12852, a 5-HT4 agonist for gastroparesis, positioning it as a direct competitor pursuing an alternative mechanism for the same chronic gastroparesis indication. It is a comparable small clinical-stage GI developer competing for the same unmet need and prescriber audience.
• RedHill Biopharma: RedHill Biopharma is a specialty pharma company focused on gastrointestinal diseases, including commercial products such as Talicia and Movantik. It is a comparable smaller GI-specialty company with commercial experience in gastroenterology that could overlap with CIN-102's launch market.
• Vanda Pharmaceuticals: Vanda Pharmaceuticals is a small specialty pharmaceutical company developing treatments for GI and CNS conditions, including tradipitant for gastroparesis. It is comparable as another small-cap developer pursuing the same gastroparesis indication with overlapping prescriber and regulatory pathways.
• Concert Pharmaceuticals: Concert Pharmaceuticals pioneered the use of deuterium chemistry to improve pharmacokinetic and safety profiles of existing drugs, the same core technology approach CinDome uses for deudomperidone. It is a comparable technology-platform peer validating the broader deuteration approach to drug development.

Broad incumbents

• Takeda Pharmaceutical: Takeda is a global pharmaceutical company with a large gastroenterology portfolio (including products such as Entyvio and Amitiza) and substantial GI commercial infrastructure. It is comparable as a broad incumbent in GI that could partner with, acquire, or compete against CinDome in the gastroparesis space.
• AbbVie: AbbVie operates a major gastroenterology franchise (e.g., Humira, Skyrizi, Rinvoq, Linzess) and has significant GI commercial infrastructure. It is a broad incumbent comparable in the sense that it serves the same gastroenterology prescribers and could be a strategic acquirer or competitor for the gastroparesis opportunity.
• Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is a GI-focused specialty pharmaceutical company (Linaclotide/Linzess franchise). It is a comparable GI-specialized company with established gastroenterology commercial reach and could be a logical strategic partner or acquirer for a gastroparesis asset like CIN-102.
• Salix Pharmaceuticals (Bausch Health): Salix is a leading gastroenterology-focused specialty pharmaceutical business within Bausch Health with deep relationships with U.S. gastroenterologists. It is a broad GI incumbent comparable as a potential commercial partner for CinDome's specialty gastroparesis launch given its established specialty GI salesforce.

Others

• CinRx Pharma: CinRx Pharma is the parent/lead investor of CinDome and operates a hub-and-spoke model advancing multiple clinical-stage biopharmaceutical companies. It is comparable as the corporate parent that provides shared scientific, technical, and clinical development resources underpinning CinDome's development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CinDome Pharma